Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27798348 | 0.90 | ALOX5 (0.34) | GAAMAPTALOX5NPC1RAB9A | |
| SCHEMBL15681088 | 0.87 | GAA (0.38) | GAAEPHX2NFKB1NFKB2RELA | |
| SCHEMBL2840941 | 0.86 | ALDH1A1 (0.33) | GAAAKR1B1MAPTSMN1; SMN2 | |
| SCHEMBL2843497 | 0.85 | GPR35 (0.34) | AKR1B1MAPT | |
| SCHEMBL2843494 | 0.85 | GPR35 (0.34) | AKR1B1MAPT | |
| SCHEMBL7346699 | 0.78 | ERN1 (0.36) | AKR1B1MAPT | |
| SCHEMBL30767932 | 0.76 | GAA (0.45) | GAAEPHX2NFKB1NFKB2RELA | |
| SCHEMBL653580 | 0.76 | GAA (0.45) | GAAEPHX2NFKB1NFKB2RELA | |
| SCHEMBL653581 | 0.76 | GAA (0.45) | GAAEPHX2NFKB1NFKB2RELA | |
| SCHEMBL5133011 | 0.76 | GAA (0.45) | GAAEPHX2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241564-B1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARM CO LTD (JP) | 2014-04-30 | — | — | EP | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8299255-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299255-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2010-12-16 | — | — | US | disclosed |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2241564-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | MC2R, GHRHR, REN | GAA 1990/4885EPHX2 3729/4885NFKB1 1336/4885 |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | GHSR, GHRHR, GNRHR | GAA 2094/4885EPHX2 4436/4885NFKB1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.